Professor Justin Stebbing MA, FRCP, FRCPath, PhD
Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College Healthcare NHS Trust.
Professor Justin Stebbing specialises in a range of malignancies (breast, GI and lung, melanoma and other solid tumours and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook junior doctor training and a residency at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew's Hospitals. Professor Stebbing’s original PhD research investigated the interplay between the immune system and cancer; he was appointed a senior lecturer in 2007, and a Professor in 2009.
Professor Stebbing has published over 500 peer-reviewed papers in journals such as the Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine, as well as writing regularly for national newspapers and presenting new data on optimal cancer therapies at the major international conferences. His focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumour cells. His laboratory work is concentrated on new druggable target discovery. The charity Action Against Cancer www.aacancer.org has been set up to support Justin's work which concentrates on drug development and has the ambitious goal of developing cures.
He is a Fellow of the Royal College of Physicians, the American Board of Internal Medicine and the Royal College of Pathologists, and sits on the advisory Boards of a number of international cancer committees. He chairs the World Vaccine Congress and the Irish Cancer Society oversight committee and is on the editorial board of a number of world leading general medical and cancer journals such as the Journal of Clinical Oncology and the Lancet Oncology; he was awarded the Silvia Lawler prize in 2015. Recently, Justin's team published in Nature Medicine the discovery of a new cancer-causing gene which we have now implicated in breast, gastro-intestinal, lung and other solid tumours. The National Institute for Health Research (NIHR) awarded Justin Stebbing its first translational research professorship in oncology, aiming to bridge the gap between the laboratory and the patient to ensure therapy is personalised. The focus of this is understanding why some patients with cancer relapse, and developing a program to reverse this and prevent it. With the excellent research record we have at Imperial College London and the clinical expertise from Imperial College Healthcare NHS Trust, we believe we are ideally placed to achieve this.
He has an extensive clinical practice and links this to a wide number of translational research studies. In 2016 Justin was internationally recognised with his appointment as co-Editor-in-Chief of Oncogene (Nature Publishing Group's cancer journal) and election to the American Society for Clinical Investigation. He has broad experience in medico-legal work, causation, condition and prognosis and has been an expert witness in court on > 30 occasions, acting for both sides, and has significant clinical governance experience in his every day large clinical practice.